Understanding Hip Joint Wear

The hip is a ball-and-socket joint that relies on a layer of articular cartilage — and a rim of fibrocartilage called the labrum — for smooth, painless movement. Problems can arise from injury, repetitive strain, joint shape abnormalities, or early arthritis, causing anything from a dull ache in the groin or buttock to sharper pain, stiffness, and reduced walking distance.

Initial management usually involves physiotherapy, activity modification, and pain relief. When these measures provide insufficient benefit, options widen to include injectable treatments and, for more significant structural damage, surgical approaches. The right choice depends on the degree of joint damage, the patient's overall health, and realistic expectations about what each option can and cannot achieve.

What ChondroFiller Is

ChondroFiller is a Class III CE-marked medical device manufactured by Meidrix Biomedicals in Germany. It is an acellular type I collagen hydrogel — a liquid gel that self-sets within approximately three to five minutes of being placed in the joint. Because it contains no cells of its own, it works by providing a scaffold structure that attracts the patient's own progenitor cells into the defect, where they can begin to lay down new cartilage-like tissue over the following months.

The device is available in the UK under prescription and can be delivered either by ultrasound-guided injection as an outpatient procedure, or arthroscopically during keyhole surgery. When used as a non-surgical treatment for the hip, it is administered as an ultrasound-guided outpatient injection — no incision, no stitches, no general anaesthetic, and no inpatient admission.

It is important to understand what ChondroFiller is not. It is not a pain-killer, not a lubricant in the manner of hyaluronic acid, and not a cure for arthritis. It is a biologically active scaffold with the potential to support cartilage repair; results vary and cannot be guaranteed.

How the ChondroFiller Injection Is Delivered

For hip joint applications, the ChondroFiller injection is performed under ultrasound guidance. Imaging allows the clinician to direct a fine needle to the precise location within the joint where the gel is needed, improving accuracy and reducing the risk of misplacement. The procedure is carried out in a single outpatient visit, after which the patient can normally leave the clinic the same day.

Following the injection, a structured physiotherapy and rehabilitation programme is typically recommended to support joint recovery and optimise the conditions for tissue regeneration. The gel is gradually resorbed and replaced over an expected period of one to two years as the body's own repair process proceeds.

Patient selection matters. Clinical experience indicates that the ChondroFiller injection is most likely to be of benefit for ICRS grade I to IV cartilage defects up to approximately six square centimetres in size, including focal lesions associated with early arthritis or labrum-related cartilage damage. Advanced joint degeneration, systemic inflammatory arthritis, and significant joint malalignment are among the factors that may make it unsuitable.

What the Evidence Suggests

Published clinical data on ChondroFiller across multiple joints include hip-specific outcome reporting using the modified Harris Hip Score (mHHS). In published series, mHHS has improved by more than 30 points from baseline in hip patients treated with ChondroFiller. Magnetic resonance imaging using MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) scoring in hip studies has reached around 80 and above at follow-up, indicating high-quality defect fill and tissue integration.

These figures are drawn from manufacturer-sponsored clinical investigations and independent published literature. They represent group-level findings, not individual guarantees. Individual outcomes depend on defect size, patient biology, rehabilitation adherence, and other factors a specialist will assess.

ChondroFiller has an exceptionally low complication rate. Across more than 19,000 units sold since 2013, no serious incidents have been reported. The overall complaint rate in the published clinical evaluation report is below 0.1%.

ChondroFiller and the Broader Treatment Landscape

ChondroFiller is one option in a spectrum of treatments for hip joint pain. Corticosteroid injections and hyaluronic acid injections focus on symptom management but do not actively support cartilage repair. Platelet-rich plasma adds biological support but no structural scaffold. ChondroFiller provides both a structural matrix and a biological stimulus for progenitor cell recruitment — an approach sometimes described as biologic scaffold-mediated repair.

For patients with larger cartilage defects, more complex structural damage, or lesions that are less accessible via injection, a surgical approach may be more appropriate. Liquid Cartilage is a separate and distinct option from ChondroFiller: it is Professor Paul Y. F. Lee's keyhole (arthroscopic) surgical protocol, which delivers the ChondroFiller scaffold during surgery alongside biological adjuncts such as platelet-rich fibrin and, where indicated, the patient's own mesenchymal stem cells. Liquid Cartilage is a surgical procedure involving theatre, anaesthetic, and a structured recovery programme — it is not an injection and should not be confused with the ChondroFiller injection described in this article. Which pathway is appropriate is something a specialist will determine at assessment.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.

Meidrix Biomedicals. ChondroFiller liquid — Version 09 Clinical Evaluation Report, April 2025.